Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M
In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at $30.62 on Monday, when the company proposed the offering after market hours. Intra-Cellular shares rose sharply on Dec. 23 after FDA approved the company’s Caplyta lumateperone to treat schizophrenia. Underwriters are J.P. Morgan, SVB Leerink, Evercore, Cantor Fizgerald, Canaccord Genuity and JMP Securities (see “Unanticipated Approval Lifts Intra-Cellular Shares”).

Biomedical software company nference raises $60M B round
nference Inc. raised $60 million in a series B round from new investors Mayo Clinic and NTT Venture Capital, and from existing investors Matrix Partners and Matrix Capital. The company is developing a software platform to synthesize biomedical information, which can then be used to guide drug discovery and clinical research. ...